SCHEMBL2368489

SCHEMBL2368489

Cc1cccc(CNc2nc(N(CCO)CCO)nc3sc(C)c(-c4ccccc4)c23)n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKCI P41743 1/20 0.41
CCNE2 O96020 4/20 0.38
CCNE1 P24864 4/20 0.38
CDK2 P24941 4/20 0.38
KCNH2 Q12809 2/20 0.38
FGFR1 P11362 1/20 0.36
ESR1 P03372 1/20 0.36
RXFP1 Q9HBX9 1/20 0.36
ALDH1A1 P00352 3/20 0.35
HPGD P15428 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
KDM4E B2RXH2 1/20 0.35
PRUNE1 Q86TP1 1/20 0.35
LMNA P02545 1/20 0.35
CSNK2A2 P19784 2/20 0.35
CSNK2B P67870 2/20 0.35
CSNK2A1 P68400 2/20 0.35
TGM2 P21980 2/20 0.35
CDK1 P06493 1/20 0.33
CDK5 Q00535 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2368725 0.92 MEN1 (0.38) PRKCICCNE2CCNE1CDK2KCNH2
SCHEMBL2368892 0.89 KCNH2 (0.48) PRKCICCNE2CCNE1CDK2KCNH2
SCHEMBL2368992 0.85 PRUNE1 (0.37) CCNE2CCNE1CDK2KCNH2ALDH1A1
SCHEMBL2368838 0.85 CCNE2 (0.41) CCNE2CCNE1CDK2ALDH1A1HPGD
SCHEMBL2368642 0.84 ESR1 (0.47) CCNE2CCNE1CDK2KCNH2ESR1
SCHEMBL2369221 0.83 PRKCI (0.43) PRKCIKCNH2FGFR1ESR1RXFP1
SCHEMBL2368043 0.83 PRKCI (0.45) PRKCICCNE2CCNE1CDK2KCNH2
SCHEMBL2368637 0.82 KCNA5 (0.43) PRKCICCNE2CCNE1CDK2KCNH2
SCHEMBL2368869 0.81 PRKCI (0.43) PRKCIKCNH2FGFR1ESR1RXFP1
SCHEMBL2369027 0.78 FGFR1 (0.54) PRKCIFGFR1ESR1ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8022076-B2 Thieno[2,3-d]pyrimidine derivatives as potassium channel modulators; antiarrhythmia agents XENTION LIMITED (GB) 2011-09-20 US disclosed
EP-1641803-B3 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS XENTION LTD (GB) 2010-12-08 EP disclosed
EP-1641803-B1 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS XENTION LTD (GB) 2009-03-18 EP disclosed
EP-1641803-A1 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS Xention Discovery Limited (GB) 2006-04-05 EP disclosed
US-20050026935-A1 Compounds XENTION DISCOVERY LTD. 2005-02-03 US disclosed
WO-2004111057-A1 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS XENTION DISCOVERY LIMITED (GB) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050026935-A1 Compounds KCNJ11, KCNJ1, KCNH1 PRKCI 2326/4885CCNE2 4258/4885CCNE1 3789/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.